

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/748,177
		Filing Date	December 31, 2003
		First Named Inventor	LEVY, Andrew
		Group Art Unit	1634
(use as many sheets as necessary)		Examiner Name	GOLDBERG, JEANINE ANNE
Sheet	2	of	76
		Attorney Docket Number	P-7339-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B	Bublin, et al, Eur Heart J. 2003; 24:2099-2107	<input type="checkbox"/>
	C	De Bacquer, et al, Atherosclerosis 2001; 157:161-1666	<input type="checkbox"/>
	D	Hong, et al, Hum Hered 1997; 47:283-7	<input type="checkbox"/>
	E	HOPE Study Investigators NE J. Med 2000;342:154-160	<input type="checkbox"/>
	F	Lind, et al, Angiology 2003; 54:401-410	<input type="checkbox"/>
	G	Nishikawa, et al, Nature 2000; 404:787-790	<input type="checkbox"/>
	H	Ohgami, et al, J Diabetes Complic 2002; 16:56-59	<input type="checkbox"/>
	I	Stamler, et al, Diabetes Care 1993; 16: 434-444	<input type="checkbox"/>
	J	Steinberg D, (1997) "Low density lipoprotein oxidation and its pathobiological significance." J Biol Chem; 272-20963-6	<input type="checkbox"/>
	K	Williams, et al, (1992) "Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis. Atherosclerosis; 94:153-159	<input type="checkbox"/>
	L	Brown, et al, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease." NE J Med 2001; 345: 1538-92	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/748,177
		Filing Date	December 31, 2003
		First Named Inventor	LEVY, Andrew
		Group Art Unit	1634
(use as many sheets as necessary)		Examiner Name	GOLDBERG, JEANINE ANNE
Sheet	3 of 6	Attorney Docket Number	P-7339-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	M	GISSI, Lancet 1999; 354:4477-55	<input type="checkbox"/>
	N	Hodis, et al, Circulation 2002; 106:1453-59	<input type="checkbox"/>
	O	Jiang, et al, J Biol Chem 2002; 277:31850-6	<input type="checkbox"/>
	P	Levy, et al, J Am Coll Card 2002; 40: 1984-90	<input type="checkbox"/>
	Q	Marchioli, et al, Lipids; 2001; 36 Suppl: S53-63	<input type="checkbox"/>
	R	Melamed-Frank, et al, Blood 2001; 98: 3693-98	<input type="checkbox"/>
	S	Steinberg, et al, Circulation 2002; 105: 2107-2111	<input type="checkbox"/>
	T	UK Prospective Study Group Diab Care 1998; 21: 1271-1277	<input type="checkbox"/>
	U	Waters, et al, JAMA 2002; 288: 2342-40	<input type="checkbox"/>
	V	Witztum, et al, Trends Cardio Med 2001; 11:93-102	<input type="checkbox"/>
	W	Barany, PCR Methods and Applic., 1:5 (1991)	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/748,177
		Filing Date	December 31, 2003
		First Named Inventor	LEVY, Andrew
		Group Art Unit	1634
(use as many sheets as necessary)		Examiner Name	GOLDBERG, JEANINE ANNE
Sheet	4	of	76
		Attorney Docket Number	P-7339-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	X	Barany, Proc. Natl Acad. Sci., 88: 189 (1991)	<input type="checkbox"/>
	Y	Brown, et al, N Eng J Med 2001; 345: 1583-1592	<input type="checkbox"/>
	Z	Fahy, et al, "Self-sustained sequence replication (3SR): an isothermal transcription-based amplification system alternative to PCR." PCR Meth. Appl., 1:25-33 (1991)	<input type="checkbox"/>
	AA	Guatelli, et al, Proc. Natl Acad. Sci., 87:1874-1878 (1990)	<input type="checkbox"/>
	BB	Mullis, PCR Methods Applic. 1:1 (1991)	<input type="checkbox"/>
	CC	The Heart Outcomes Prevention Evaluation Study Investigators N Eng J Med 2000; 342: 154-160	<input type="checkbox"/>
	DD	Wu and Wallace, Genomics 4: 560 (1989)	<input type="checkbox"/>
	EE	Barlow and Lehrach, Trends Genet., 3:167 (1987)	<input type="checkbox"/>
	FF	Conner, et al, Proc. Natl Acad. Sci. 80: 278-282 (1983)	<input type="checkbox"/>
	GG	Farr, et al, Proc. Natl. Acad. Sci. 85: 1629-1633 (1988)	<input type="checkbox"/>
	HH	Gogos, et al, "Detection of single base mismatches of thymine and cytosine residues by potassium permanganate and hydroxylamine in the presence of tetralkylammonium salts." Nucl. Acids Res., 18: 6807-6817 (1990)	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/748,177
		Filing Date	December 31, 2003
		First Named Inventor	LEVY, Andrew
		Group Art Unit	1634
(use as many sheets as necessary)		Examiner Name	GOLDBERG, JEANINE ANNE
Sheet	5	of	76
		Attorney Docket Number	P-7339-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	II	Kwok, et al, Nucl. Acids Res., 18:999 (1990)	<input type="checkbox"/>
	JJ	Lyons, et al, Science 249: 655-659 (1990)	<input type="checkbox"/>
	KK	Perlman and Butow, Science 246: 1106 (1989)	<input type="checkbox"/>
	LL	Urdea, et al, Gene 61: 253-264 (1987)	<input type="checkbox"/>
	MM	Vogelstein, et al, N Eng. J. Med. 319: 525-532 (1988)	<input type="checkbox"/>
	NN	Abrams, et al, Genomics 7: 463-475 (1990)	<input type="checkbox"/>
	OO	Borrensens, et al, Proc. Natl Acad. Sci. USA 88: 8405 (1991)	<input type="checkbox"/>
	PP	Hayashi, Sekya and colleagues PCR Meth. Appl. 1: 34-38 (1991)	<input type="checkbox"/>
	QQ	Lerman and Silverstein, Meth Enzymol, 155: 482-501 (1987)	<input type="checkbox"/>
	RR	Liu and Sommer, PCR Methods Applic 4: 97 (1994)	<input type="checkbox"/>
	SS	Orita, et al, Genomics 5: 874-879 (1989)	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/748,177
		Filing Date	December 31, 2003
		First Named Inventor	LEVY, Andrew
		Group Art Unit	1634
(use as many sheets as necessary)		Examiner Name	GOLDBERG, JEANINE ANNE
Sheet	6	of	76
		Attorney Docket Number	P-7339-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	TT	Scholtz, et al, Hum. Mol. Genet. 2: 2155 (1993)	<input type="checkbox"/>
	UU	Sheffield, et al, Proc Natl. Acad. Sci. 86: 232-236 (1989)	<input type="checkbox"/>
	VV	Smith, et al, Genomics 3:217-223 (1988)	<input type="checkbox"/>
	WW	Wartell, et al, Nucl. Acids Res., 18: 2699-2701 (1990)	<input type="checkbox"/>
	XX	Campo, et al, Cardiovasc Drug Rev 1997; 15: 157-173	<input type="checkbox"/>
	YY	Kita, et al, PNAS USA 1987; 84: 7725	<input type="checkbox"/>
	ZZ	Mak, et al, Pharma Res. 2002; 45: 27-33	<input type="checkbox"/>
	a	Meng, et al, Bioorg Med Chem Ltrs 2002; 12: 2545-48	<input type="checkbox"/>
	b	Sagach, et al, Pharma Res 202; 45: 435-439	<input type="checkbox"/>
	c	Yoshida, et al, Atheroscler 2002; 162: 111-117	<input type="checkbox"/>
			<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.